|
gptkbp:instanceOf
|
gptkb:drug
combination drug
|
|
gptkbp:activeIngredient
|
gptkb:elexacaftor
gptkb:ivacaftor
gptkb:tezacaftor
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:R07AX31
|
|
gptkbp:brand
|
gptkb:Trikafta
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trikafta
|
|
gptkbp:indication
|
patients with at least one F508del mutation in the CFTR gene
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:marketedAs
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
CFTR modulator
|
|
gptkbp:otherName
|
gptkb:elexacaftor/tezacaftor/ivacaftor
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
headache
upper respiratory tract infection
increased liver enzymes
|
|
gptkbp:usedFor
|
cystic fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|